fda compounding semaglutide crackdown news today The is cracking down on ‘misleading’ compounded GLP-1s from telehealth companies., Compounded weight loss drugs are not FDA-approved, which means the agency does not review their safety, Hims is in the crosshairs.

Next, patients meet with their provider via video visit to review the lab results and answer any additional questions their provider may have to inform a personalized treatment plan

however, the precise contribution of glucagon receptor activation to the overall gastrointestinal side effect burden in humans has not yet been established, and this remains an area of active investigation

Its multi-incretin profile has made it a high-interest compound in research involving body-weight models, metabolic signaling, receptor activity, glycemic endpoints, energy expenditure, and body-composition research

This could lead to issues like bacterial contamination, impurities, and the use of lower-grade ingredients